IL283609A - Treatment by oral administration of 6, 8-bis-benzylthio-octanoic acid - Google Patents

Treatment by oral administration of 6, 8-bis-benzylthio-octanoic acid

Info

Publication number
IL283609A
IL283609A IL283609A IL28360921A IL283609A IL 283609 A IL283609 A IL 283609A IL 283609 A IL283609 A IL 283609A IL 28360921 A IL28360921 A IL 28360921A IL 283609 A IL283609 A IL 283609A
Authority
IL
Israel
Prior art keywords
benzylthio
bis
octanoic acid
oral therapy
therapy
Prior art date
Application number
IL283609A
Other languages
English (en)
Hebrew (he)
Original Assignee
Rafael Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rafael Pharmaceuticals Inc filed Critical Rafael Pharmaceuticals Inc
Publication of IL283609A publication Critical patent/IL283609A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL283609A 2018-12-20 2021-06-01 Treatment by oral administration of 6, 8-bis-benzylthio-octanoic acid IL283609A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782938P 2018-12-20 2018-12-20
US201962834478P 2019-04-16 2019-04-16
PCT/US2019/067763 WO2020132401A1 (en) 2018-12-20 2019-12-20 Oral therapy using 6,8-bis-benzylthio-octanoic acid

Publications (1)

Publication Number Publication Date
IL283609A true IL283609A (en) 2021-07-29

Family

ID=71101630

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283609A IL283609A (en) 2018-12-20 2021-06-01 Treatment by oral administration of 6, 8-bis-benzylthio-octanoic acid

Country Status (11)

Country Link
US (1) US20220040133A1 (https=)
EP (1) EP3897606A4 (https=)
JP (1) JP2022514084A (https=)
KR (1) KR20210105913A (https=)
CN (1) CN113543779A (https=)
AU (1) AU2019405976A1 (https=)
CA (1) CA3121645A1 (https=)
IL (1) IL283609A (https=)
MX (1) MX2021007324A (https=)
TW (1) TW202038930A (https=)
WO (1) WO2020132401A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240033277A1 (en) * 2020-12-03 2024-02-01 New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special Methods for treating autoimmune diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263653B2 (en) * 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
WO2009110859A1 (en) * 2008-03-04 2009-09-11 Robert Shorr Modulation of enzymatic structure, activity, and/or expression level
WO2011143590A1 (en) * 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
MA45865A (fr) * 2016-08-07 2021-04-14 Wistar Inst Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1
US20190160034A1 (en) * 2017-03-20 2019-05-30 Indiana University Research And Technology Corporation Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer
WO2019055525A1 (en) * 2017-09-12 2019-03-21 Raj Selvaraj FORMULATION OF SOLID NANOPARTICLES OF WATER-INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD CURING
US20210000778A1 (en) * 2018-04-16 2021-01-07 Rafael Pharmaceuticals, Inc. Therapeutic methods and compositions for treating prostate cancer using 6,8-bis-benzylthio-octanoic acid
CN112469405A (zh) * 2018-07-23 2021-03-09 拉斐尔制药股份有限公司 使用6,8-双(苄硫基)辛酸治疗胰腺癌的治疗方法和组合物
US20220054445A1 (en) * 2018-12-20 2022-02-24 Rafael Pharmaceuticals, Inc. Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor
MX2021011250A (es) * 2019-03-19 2022-02-11 Rafael Pharmaceuticals Inc Metodos y composiciones terapeuticas para tratar linfoma usando acido 6,8-bis-benciltio-octanoico.

Also Published As

Publication number Publication date
KR20210105913A (ko) 2021-08-27
WO2020132401A1 (en) 2020-06-25
CN113543779A (zh) 2021-10-22
JP2022514084A (ja) 2022-02-09
AU2019405976A1 (en) 2021-06-24
US20220040133A1 (en) 2022-02-10
EP3897606A1 (en) 2021-10-27
EP3897606A4 (en) 2022-08-31
MX2021007324A (es) 2021-08-16
CA3121645A1 (en) 2020-06-25
TW202038930A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
GB2592117B (en) Oral solution cannabinoid formulations
CA207119S (en) Oral irrigator
CA193485S (en) Oral irrigator
IL285078A (en) Delicious formulations
GB201900702D0 (en) Therapy
IL292502A (en) Therapeutic methods using vadadustat
IL288937A (en) Improved treatment using eyp001
CA184554S (en) Oral exerciser
HUE064843T2 (hu) Orális oldat kiszerelés
CA187143S (en) Oral irrigator
GB201707503D0 (en) New Therapy 3
SG11202104371XA (en) 1,3,4-oxadiazolone compound and pharmaceutical
CA187183S (en) Oral irrigator
IL283609A (en) Treatment by oral administration of 6, 8-bis-benzylthio-octanoic acid
GB201918752D0 (en) New therapy
GB201912191D0 (en) New therapy
EP4044960C0 (en) DENTAL ROD
GB201901803D0 (en) Medical patent 3189
GB201901804D0 (en) Medical patent 41989
GB201919177D0 (en) Novel therapy
GB201919036D0 (en) Therapy
GB201916983D0 (en) Therapy
GB201914848D0 (en) Therapy
GB201912423D0 (en) Novel therapy
GB201913797D0 (en) Therapy